Tempus to acquire Paige for $81m.

Tempus, a medical technology company, agreed to acquire Paige, an AI company specializing in digital pathology, for $81m. “As we embark upon building the largest foundation model that’s ever been built in oncology, the acquisition of Paige substantially accelerates our efforts. Paige is a leader in digital pathology and has amassed one of the most comprehensive digital pathology datasets in the world through its relationship with Memorial Sloan Kettering Cancer Center. We believe both the Paige team, with their deep generative AI experience, and the dataset they have built, will be catalytic across all of our AI efforts,” Eric Lefkofsky, Tempus Founder and CEO.